Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, and Acute Lymphoblastic Leukemia research.
Menin inhibition with revumenib for <i>NPM1</i>-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007
Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007
Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed <i>NPM1-</i>m or <i>KMT2A</i>-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory <i>NPM1</i>-m or <i>KMT2A</i>-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) <i>KMT2Ar</i> Acute Leukemia
Revumenib Monotherapy in Patients with Relapsed/Refractory <i>KMT2Ar</i> Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
Revumenib Monotherapy in Patients with Relapsed/Refractory <i>KMT2Ar</i> Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
( <i>R</i> )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible